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Abstract
Background: Ovarian cancer is the second most prevalent gynecologic cancer in women. However, it is by far the most
lethal. This is generally attributed to the absence of easily detectable markers specific to ovarian cancers that can be used
for early diagnosis and specific therapeutic targets.
Methodology/Principal Findings: Using end point PCR we have found that a family of retrogenes, previously thought to be
expressed only in the male testis during spermatogenesis in man, are also expressed in normal ovarian tissue and a large
percentage of ovarian cancers. In man there are at least eleven such autosomal retrogenes, which are intronless copies of
genes on the X chromosome, essential for normal spermatogenesis and expressed specifically in the human testis. We
tested for the expression of five of the known retrogenes, UTP14C, PGK2, RPL10L, RPL39L and UBL4B in normal human ovary
and ovarian cancers.
Conclusions/Significance: We propose that the activation of the testis specific retrogenes in the ovary and ovarian cancers
is of biological significance in humans. Because these retrogenes are specifically expressed in the ovary and ovarian cancers
in the female they may prove useful in developing new diagnostic and/or therapeutic targets for ovarian cancer.
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Introduction
Although ovarian cancer is the second most prevalent
gynecological cancer in women, it is by far the most lethal. It is
the fifth leading cause of cancer-related death among women in
the United States even though it represents less than 4% of the
total cancers diagnosed. In 2008, it is estimated that there will be
about 21,650 new cases of ovarian cancer diagnosed in the United
States and there will be 15,520 attributed deaths[1]. Approx-
imately 45% of women diagnosed with ovarian cancer will die
within 5 years of diagnosis. This compares with 14% of those
diagnosed with breast cancer and 30% with cancer of the cervix
and uterus[2]. This high level of morbidity is thought to be due to
an inability to recognize the presence of early stage ovarian cancer
in the clinical setting due to the lack of cancer specific markers that
could aid early diagnosis and post operative monitoring for disease
recurrence. This situation is clearly illustrated by the fact that
when ovarian cancers are diagnosed at stage I and II 82% of
victims survive five years after diagnosis whereas those diagnosed
at stage III and IV have a five year survival rate of 25%. Only
32% of cases are diagnosed at stage I and II, compared with 68%
at stage III and IV[3]. There is therefore a great need to identify
patterns of gene expression that are specific to ovarian cancer so
that new diagnostic and therapeutic strategies can be developed.
As part of an ongoing program studying the role of genes critical
for spermatogenesis, we previously identified a retrogene,
UTP14C, associated with male fertility in man and mouse[4–6].
Retrogenes arise when fully or partially processed mRNAs are
reverse transcribed into double stranded DNA and this DNA copy
is inserted into the genomic DNA present in the chromosomes. If
the copy is expressed as a messenger RNA and translated into a
protein the new gene is known as a functional retrogene. The gene
from which the retrogene originated is termed the progenitor
gene. In humans UTP14C is located on chromosome 13 and
originated as a reverse-transcribed copy of a gene located on the X
chromosome, UTP14A. It has recently been established that a
disproportionate number of functional autosomal retrogenes have
originated from the X chromosome and acquired male germ-line
specific function[7–9]. Several different hypotheses have been
proposed to explain this evolutionary phenomenon[10], neverthe-
less the most compelling is that of compensation for transcriptional
inactivation of the sex chromosomes that occurs in mammals when
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genesis in the male the sex chromosomes pair via a short
pseudoautosomal region during early prophase I and condense to
form a macrochromatin body known as the sex, or XY, body[11].
Unlike the autosomal chromosomes that form homologous pairs
known as synaptonemal complexes and remain transcriptionally
active throughout meiosis, the sex chromosomes are transcrip-
tionally silenced (meiotic sex chromosome inactivation) from the
time of sex body formation until meiosis is competed and haploid
spermatids form[12]. The X chromosome contains a large number
of housekeeping genes essential for normal cell function and
survival. Thus silencing of the X chromosome during male meiosis
may have some metabolic disadvantage for later stages of
spermatogenesis. Retrotransposition of X linked housekeeping
genes to the autosomes, with subsequent acquisition of testis
specific expression, is one mechanism by which such metabolic
disadvantage can be corrected during spermatogenesis without
disrupting normal function in somatic tissue[13]. In man there are
at least eleven such autosomal retrogenes that have retro-
transposed off the X chromosome and play an important role in
maintaining efficient spermatogenesis[10].
Using endpoint RT-PCR to screen cDNAs prepared from a
comprehensive panel of human tissues we found that UTP14C was
expressed not only in the male testis but also in the female ovary
and no other tissue[6]. The unexpected expression of UTP14C in
the human ovary prompted us to explore whether or not UTP14C
was also expressed in ovarian cancers. To determine if expression
of testis specific retrogenes in normal ovaries and ovarian cancers
was a general phenomenon in humans we also tested for the
expression of four other retrogenes (PGK2, RPL10L, RPL39L and
UBL4B) that were previously thought to be expressed exclusively
during spermatogenesis in the male.
Here, we present the results of our screen for the expression of
the testis specific retrogenes in normal ovarian tissue and a panel
of ovarian cancers. We propose that a pattern of testis-like
transcriptional regulation that results in retrogene expression
frequently occurs in ovarian cancers and could contribute to the
pathogenesis of this disease. In addition the unique ovarian and
ovarian-cancer specific expression of retrogene encoded products
may provide new understanding of gene expression in the female
and lead to the identification of new diagnostic and/or therapeutic
targets for ovarian cancer treatment.
Materials and Methods
Sources of Tissue Samples and RNA
Samples of pre- and post- menopausal ovaries were prospec-
tively collected during clinical-indicated surgeries performed at
Baylor College of Medicine affiliated hospitals by gynaecological
surgeons. In addition samples of flash-frozen ovarian cancers were
obtained from the Multidisciplinary Gynaecologic Tumor Bank at
The University of Texas M.D. Anderson Cancer Center
(MDACC, Houston, Texas), human total testis and ovarian
RNA was purchased from Panomics (Fremont, California, USA.
Product #NA2007) and the human RNA panel was purchased
from Clontec (Clontech Laboratories Inc., Mountain View
California USA. Master Panel II, Product #636643).
All collection was done under the approval from the
Institutional Review Board at the Baylor College of Medicine
(Protocol H-14372). Permission to use human tissues was obtained
from each patient by written consent using a form approved by the
Institutional Review Board for Baylor College of Medicine and its
affiliated institutions. Written consent was similarly obtained from
patients donating tissue samples to the Multidisciplinary Gyneco-
logic Tumor Bank at The University of Texas M.D. Anderson
Cancer Center.
RNA extraction and first strand synthesis
Prospectively collected tissue samples were placed into 10 ml of
RNAlater (Ambion, Inc. Austin Texas, USA) and stored at 220uC
until RNA extraction. RNA was extracted from weight tissue
samples by thawing in TRIzol Reagent (Invitrogen Corp.
Carlsbad California USA) followed by immediate homogenization
using a Tissue-Tearor homogenizer (BioSpec Products, Inc.
Bartlesville Oklahoma, USA). RNA was recovered using the
TRIzol Reagent protocol. RNA was resuspended in nuclease free
water and stored at 280uC. To produce cDNA 5 mg of RNA was
treated with DNase (Turbo DNA-free kit, Ambion Inc.),
precipitated and re-suspended to a concentration of 1 mg per ml.
A RETROscript Kit (Ambion, Inc.) was used for first strand
cDNA synthesis from 2 mg of RNA with a combination of
oligo(dT)18 and random(dN)15 primers. After synthesis the 20 ml
reaction mixtures were diluted to 150 ml with nuclease free water
and stored at 220u.
RT-PCR
Genes of interest were detected by end point PCR using gene
specific primers (Table 1). Reaction volumes of 20 ml of diluted
AccuPrime Super Mix II (Invitrogen, Corp.) containing 1 mlo f
cDNA and retrogene specific primers were heated to 94uC for
2 minutes then cycled 35 times through 94uC for 20 seconds,
58uC for 20 seconds, 68uC for 30 seconds, and kept at 15uC after
the final cycle. PCR products were run out on 1.75% agarose gels
Table 1. Primers used for gene expression analysis by
endpoint PCR.
Gene Primer Name Primer Sequence
UTP 14a hUTP14x3F TCCAGCTGCACACTAGAAGAAC
hUTP14x3R CTTTCAGAAACTCCATGGGCT
GT8 HumJSD59test CATTTGCTGGTTTCTGTTGGCCAG
UTP14b HumJSDLend GCCTTTGCTAAATTGCTGAATAAG
HumJSD2R AGGCTCATGGCTTGGAGAGAG
HumJSD3R TTGGCCATAATTGCCTTTGAC
PGK1 PGK1F CACTGCTCACAGAGCCCACAGC
PGK1R CTGCTTAGCCCGAGTGACAGCCTC
PGK2 PGK2F CACTGCACACCGCGCTCATAGT
PGK2R TAGCCTTGCTTGAGCCACAACTTG
RPL10 RPL10F AGGGTTCACATTGGCCAAGTT
RPL10R TAAGAGGGGGGCAGCACA
RPL10L RPL10LF GGGTCCACATTGGTCAAGTC
RPL10LR CCCAAGGAGACAGTACTGCC
RPL39 RPL39proF CCTCCTCTTCCTTTCTCCGCCATC
RPL39proR GTTCATAACAGATTCAGAGAGG
RPL39L RPL39LF S2 TGGATTCAGATGAAACCTGGT
RPL39LR S2 ATCCACCCTACTAGCACAGAGC
UBL4A UBL4AF CAGCTGACGGTGAAGGCGCTGCA
UBL4AR GTTTGACCACTAGGTTGAGCTTG
UBL4B UBL4BF TTCCTCACAGTCAAGCTGCTCCT
UBL4BR GCTGCATGATGACATTGATAGAG
doi:10.1371/journal.pone.0005064.t001
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illumination. Gels were photographed using a Kodak Gel Logic
200 Imaging System.
Results and Discussion
As part of an ongoing program studying the role of genes crucial
for spermatogenesis we previously reported the identification of a
retrogene associated with male fertility in man and mouse[4–6]. In
humans this retrogene, UTP14C, is located on chromosome 13
and originated as an intronless, reverse-transcribed copy of the X-
linked gene, UTP14A. Although the function of UTP14A and C
and their products is not known, analogy with the product from
the yeast gene, Utp14, suggests that the human peptides, UTP14A
and C, form part of the Small-Subunit (SSU) processome which is
responsible for generating 18S rRNA from its precursor, the U3
snoRNA, in the nucleolus[14,15]. Using endpoint RT-PCR to
screen cDNAs prepared from a comprehensive panel of human
tissues we found UTP14C to be expressed not only in the male
testis, but also in the female ovary[6]. This unexpected expression
of UTP14C in the human ovary prompted us to see if UTP14C was
also expressed in ovarian cancers with the hope of identifying
tissue specific markers selectively expressed in normal ovaries and
ovarian cancers. End point RT-PCR was used to detect transcripts
for UTP14A and C in primary ovarian cancers and established
ovarian cancer cell lines. Determining the expression of UTP14C
by RT-PCR is complicated by the fact that it is located within an
actively transcribed host gene, GT8. UTP14C is the result of a
retrotransposition event where an intronless DNA copy of the
UTP14A coding sequence inserted immediately upstream of the
coding region present in the terminal exon of GT8 on chromosome
13. Subsequently UTP14C has acquired a promoter that drives its
expression during spermatogenesis. Because the transcripts of
UTP14C and GT8 overlap the possibility of a single transcript
containing open reading frames from both genes arises. To
distinguish between the overlapping transcripts that are produced
from the retrogene and its host, primer pairs were designed to
specifically amplify either UTP14C or GT8 [6] and detect any
transcript that may contain both open reading frames. Fig. 1
shows the expression profiles of UTP14A, UTP14C and GT8 in a
representative sample of six different papillary serous ovarian
cancers, the most common histological subtype of this malignancy,
two clear cell and two endometrioid samples. UTP14A, the X
chromosome linked progenitor gene from which UTP14C arose,
was expressed in all of the cancer samples (lane A). Similarly, GT8,
the host gene for UTP14C, was expressed in all samples (lane C).
The spermatogenesis-associated retrogene, UTP14C, was ex-
pressed in all but one of the cancer samples (lane D). We also
tested our samples using the combination of a 59-primer specific to
GT8 (that is up stream of the UTP14C transcriptional start site)
and 39-primer specific to UTP14C (that is upstream of the GT8
transcript)[6]. The absence of a PCR product using this primer
pair confirms that a read-through mRNA, spanning both the GT8
and UTP14C genes, is not produced and establishes the
independence of the two overlapping transcripts (lane B). Similar
results were obtained for all primer combinations when a panel of
established ovarian cancer cell lines were tested under identical
conditions (2774, ES-2, TOV112D, OV90, SKOV3, TOV21G,
HEY and OVCAR3; Fig. 2). However, it should be noted that
several of the cell line samples also showed the presence of RNA
transcripts that spanned both the host gene (GT8) and UTP14C
suggesting aberrant transcriptional regulation in some of the
ovarian cancer cell lines. We have never observed transcription
that spanned both genes in human tissue samples.
The high frequency with which UTP14C was expressed in our
initial survey led us to explore the incidence of its expression in a
large panel of ovarian cancers with different clinical histology. In
aggregate, we found that that transcripts for UTP14C can be
Figure 1. RT-PCR of cDNA samples from ten Papillary Serous ovarian cancers with primers specific to UTP14A, UTP14C and GT8. Lane
A shows the product specific to UTP14A. Lane B shows the reaction product from a primer pair specific to GT8 (59 end) and UTP14C (39 end), these two
genes overlap on human chromosome 1 and the absence of a PCR product demonstrates that transcripts from the two gene are exclusive. Lane C
shows the GT8 gene specific product and, lane D, the PCR product from UTP14C. Molecular weight marker was run in lane M.
doi:10.1371/journal.pone.0005064.g001
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most common form of cancer examined, and most other cancer
subtypes. The frequency of UTP14C expression in a variety of
ovarian cancer histological subtypes is shown in Table 2.
To determine if activation of testis specific retrogenes in ovaries
and ovarian cancers is a general phenomenon the expression of
four other retrogenes, previously thought to be testis specific, was
studied. The spermatogenesis associated retrogenes tested encoded
for a variety of important cell functions: metabolic enzymes
(PGK2)[13], ribosomal proteins (RPL10L and RPL39L)[16] and
post translational protein modification (UBL4B)[17]. Primer pairs
specific to the retrogenes and their X linked progenitors were used
for molecular characterization of gene expression in the same
panel of ovarian cancer tissues previously described.
In man, phosphoglycerate kinase is encoded by two genes,
PGK1 and PGK2. Phosphoglycerate kinase converts 1.3-diphos-
phoglycerate into 3-phosphoglycerate in the glycolysis pathway.
This leads to the production of pyruvate from glucose and
fructose[18]. PGK1 is located on the X chromosome and is
ubiquitously expressed whereas PGK2, a retrotransposed copy of
PGK1, is located on chromosome 6 and shows a testis specific
expression pattern[13]. Another retrotransposed copy of PGK1 is
Figure 2. RT-PCR of cDNA from established ovarian cancer cell lines. Lane A: UTP14A specific product. Lane B: Product from primers
common to both UTP14C and GT8. This primer combination fails to give a PCR product in ovarian or ovarian cancer tissue samples. Lane C: GT8
specific RT-PCR product. Lane D: Product specific to UTP14C. Primer combinations are described in the text. Established ovarian cancer cell lines used
were 1. 2774, 2. ES-2, 3. TOV112D, 4. OV90, 5. SKOV3, 6. TOV21G, 7. HEY, 8. OVCAR3, and M, molecular size marker.
doi:10.1371/journal.pone.0005064.g002
Table 2. The frequency of retrogene expression in a panel of ovarian cancer samples as well as pre- and post- menopausal ovary
samples.
Cancer Histology UTP14a UTP14c PGK1 PGK2 RPL10 RPL10L RPL39 RPL39L UBL4A UBL4B
Pap Serous 50/51 (98%) 41/51 (80%) 48/51 (94%) 40/51 (78%) 45/51 (88%) 43/51 (84%) 50/51 (98%) 50/51 (98%) 50/51 (98%) 31/51
(61%)
Mixed 17/17 (100%) 10/17 (59%) 17/17 (100%) 13/17 (76%) 12/17 (71%) 13/17 (76%) 16/17 (94%) 17/17 (100%) 17/17 (100%) 5/17 (29%)
Endometrioid 9/9 (100%) 1/9 (11%) 7/9 (78%) 3/9 (33%) 7/9 (78%) 4/9 (78%) 9/9 (100%) 9/9 (100%) 7/9 (78%) 9/9 (100%)
Clear Cell 7/7 (100%) 1/7 (14%) 7/7 (100%) 4/7 (57%) 6/7 (86%) 4/7 (57%) 7/7 (100%) 7/7 (100%) 7/7 (100%) 2/7 (29%)
MMMT 1/1 (100%) 1/1 (100%) 1/1 (100%) 0/1 (0%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%)
AGCT 7/8 (88%) 2/8 (25%) 8/8 (100%) 4/8 (50%) 7/8 (88%) 5/8 (65%) 7/8 (88%) 7/8 (88%) 8/8 (100%) 6/8 (75%)
Sex Cord 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%)
Transitional 2/2 (100%) 1/2 (50%) 2/2 (100%) 2/2 (100%) 2/2 (100%) 2/2 (100%) 1/2 (50%) 2/2 (100%) 2/2 (100%) 2/2 (100%)
Carcinoid 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 0/1 (0%)
Immature Teratoma 1/1 (100%) 0/1 (0%) 1/1 (100%) 1/1 (100%) 0/1 (0%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 1/1 (100%) 0/1 (0%)
Pre-Ovary 5/5 (100%) 4/5 (80%) 5/5 (100%) 4/5 (80%) 5/5 (100%) 5/5 (100%) 5/5 (100%) 5/5 (100%) 5/5 (100%) 3/5 (60%)
Post-Ovary 9/9 (100%) 7/9 (78%) 9/9 (100%) 6/9 (67%) 9/9 (100%) 9/9 (100%) 9/9 (100%) 9/9 (100%) 9/9 (100%) 4/9 (44%)
Abbreviations: MMMT, Malignant Mixed Mullerian Tumor. AGCT, Adult Granulosa Cell Tumor. Pre-, Premenopausal. Post-, Postmenopausal.
doi:10.1371/journal.pone.0005064.t002
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protein and is probably inactive as no ESTs (Expressed Sequence
Tags) could be found in the human database. Over expression of
the PGK1 protein has been linked to paclitaxel resistance[19] and
tumor angiogenesis[20]. In addition, PGK1 protein levels are
elevated in serum from pancreatic duct adenocarcinoma pa-
tients[20,21]. Thus, it appears that PGK1 over expression may be
of biological significance in some cancers. Detection of PGK1 and
PGK2 in a representative panel of ovarian cancers, testis and pre
and post-menopausal ovaries is shown in Fig. 3. Expression of
PGK2 was detected in all ovarian tumor types with the highest
frequency in papillary serous (78%) and mixed histology (76%)
tumors (Table 2). As expected for a housekeeping gene, PGK1 was
expressed in all tumor samples. However, due to the small sample
size of the rare ovarian cancer subtypes the true frequency of PGK2
expression in these tumors could not be estimated. It remains to be
determined if PGK2 expression is associated with tumor biology.
Mammalian ribosomes are made up of at least 80 ribosomal
proteins[22] of which four are encoded on the X chromo-
some[23]. Three of these, RPL10, RPL36A and RPL39, have
autosomal retrotransposed copies. Two are located on chromo-
some 14 (RPL10L and RPL36AL) and the third on chromosome 3
(RPL39L)[16]. RPL36AL is ubiquitously expressed whereas
RPL10L and RPL39L have previously been reported to be
expressed exclusively in the testis[16]. The RPL10 is also a tumor
suppressor gene and the protein it encodes is known as the tumor
suppression protein QM[24]. Reduced RPL10 expression is
associated with increasing grade of prostatic adenocarcinoma[25].
Primers specific to RPL10L and RPL39L were used to screen for
expression of these testis specific retrogenes in a panel of ovarian
cancers (Table 2; Fig. 3). Transcripts from both retrogenes were
detected in papillary serous, clear cell and endometroid samples.
RPL10L was expressed in 76% of a large ovarian tumor panel with
84% expression in papillary serous cancers, 76% in tumors with
mixed histology and 44% in endometroid tumors (Table 2).
RPL39L was expressed at even higher frequency with 98% of
papillary serous cancers containing transcript (Table 2). Expres-
sion in tumors with other histologies was 88% in AGCT (Adult
Granulosa Cell Tumor) and 100% in all other subtypes tested.
Although a direct role for the ribosomal proteins in cancer
biology is yet to be established, it should be noted that RPL39
expression is increased in breast cancer[26]. RPL39L expression
has been reported in cervical cancer[27] as well as cell lines
originating from breast, lung, prostate, colon, pancreatic and
ovarian cancers[16,20] suggesting that the retrogene RPL39L may
have an important role in the biology of a large range of cancers.
However, it should be noted that a screen for RPL39L expression
in a human tissue RNA panel resulted in the detection of this
retrogene in a large number of normal tissues suggesting that
although RPL39L expression occurs predominantly in the testis it
may not be testis specific (Fig. 4). Expression of the retrogenes
RPL10L and RPL39L in cancers could possibly enhance ribosome
production and/or translational activity. In testes, these retrogenes
are expressed during spermatogenesis just before the rapid
production of proteins that are required for sperm differentiation
and maturation.
Ubiquitin like proteins (UBLs) are post translationally bound to
a diverse group of other proteins thereby increasing the functional
diversity of the encoded proteome. UBL modified proteins are
known to influence the activity of a wide range of cell signaling
pathways[28,29]. UBL4A and UBL4B are recently identified genes
that encode small ubiquitin like proteins[17]. In mouse, the X-
linked Ubl4A is expressed in all tissue types, whereas the retrogene
Ubl4b is reported to be expressed only in elongating spermatids
during late stages of spermatogenesis in the testis[17]. Preliminary
testing for UBL4A and UBL4B expression in a human RNA panel
found that UBL4A was expressed in all tissue types tested. UBL4B,
located on chromosome 1, was expressed only in the testis (Fig. 4)
although later screening of a larger sample of pre- and post-
menopausal ovaries demonstrated that UBL4B was expressed in
normal ovarian tissues at low frequency (Table 2). Results of an
initial screen for UBL4B activation in ovarian tumor samples is
shown in Fig. 3. Table 2 shows the frequency with which UBL4A
and UBL4B expression was detected in an extensive panel of
ovarian tumor samples. As almost all cellular functions are affected
by ubiquitination it is not surprising that alterations in ubiquitin
and UBL activity have been implicated in the genesis of different
human tumor types[30]. UBL modification by SUMO-1 (small
ubiquitin-related modifier, also known as UBL1) has been directly
Figure 3. Expression of the testis specific retrogenes, and their
X linked progenitors, in ovarian cancers and normal ovarian
tissue. a. Retrogene expression in a panel of ovarian cancers was
detected by RT-PCR. Samples and cancer histology were: 1–6. Papillary
Serous, 7 & 8 Clear Cell, 9 & 10 Endometrioid, 11 pre-menopausal ovary,
12 post-menopausal ovary. Negative control C and marker M. b.
Retrogene expression in normal ovarian tissue: 1–4. pre-menopausal
ovaries, 5–8. post menopausal ovaries, negative control C and marker
M.
doi:10.1371/journal.pone.0005064.g003
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tumors[31] and is known to play an important role in
spermatogenesis[32].
Screening for retrogene expression in normal pre- and post-
menopausal ovaries revealed that the retrogenes are not expressed
in all women. The X linked progenitor gene is expressed in all
cases (Table 2; Fig. 3) as would be expected for genes encoding
essential gene functions that are ubiquitously expressed in the
human body. However, retrogene expression in healthy ovarian
tissue may be as high as 100% (RPL10L and RPL39L) of the
samples tested or as low as 44% (UBL4B). This suggests that, for at
least some of the retrogenes, expression in the ovary is limited to
particular individuals within the general population. Most work on
the spermatogenesis specific retrogenes has been done on the
mouse model where ovarian expression of these genes is absent.
Expression of these retrogenes in the human ovary may be a
species specific phenomenon and may reflect an important
biological difference between man and mouse. The retrogene
and progenitor X gene specific primers were tested against a panel
of RNAs from different human tissues to confirm the ubiquitous
expression of the X linked progenitor and limited expression of the
retrogene (Fig. 4). In most cases retrogene expression was limited
to the gonads in man. Whether there is any relationship between
expression of testis specific retrogenes in the human ovary and
increased probability of cancer development is yet to be
established.
Of special note is our observation that the X linked progenitor
genes are not always expressed in all ovarian cancer samples.
When this was the case the complimentary retrogene was always
expressed suggesting that the retrogene was compensating for the
loss of gene activity on the X chromosome in a manner similar to
that which occurs when the X chromosome is transcriptionally
silenced during male meiosis. The deletion of segments of the X
chromosome in ovarian cancer cells and subsequent loss of
heterozygosity is well documented[33]. Such deletions could result
in the loss of genes which have retrotransposed copies. The loss of
a copy of PGK1 due to deletions within the X chromosome has
been previously reported in a variety of ovarian cancer histological
subtypes[34]. Such loss could be biologically significant if the
deleted copy is from the active X chromosome or if both copies of
a gene are transcriptionally active in normal cells.
The high frequency of spermatogenesis specific retrogene
activation in ovarian cancers reported in this paper has important
theoretical and practical implications for ovarian cancer treatment
and biology. As these retrogenes are expressed only in the ovary
and/or ovarian tumors and nowhere else in the female body the
potential to develop tumor specific markers and therapies presents
itself. Precedence for this is established by the expression of
cancer/testis (CT) genes and antigens in a broad range of human
tumors and is a phenomenon that has been recognized for some
time[35,36]. Expression of CT antigens in cancers was first
reported with MAGE-1 in 1991, even though at the time it was
thought to be a gene expressed specifically in human melanoma
tumors[37] and its expression in the testis was not recognized.
Later reports added MAGE-3 and BAGE to the list of CT antigens
that are expressed in tumors but not expressed in normal tissues
other than the testis[38,39]. Identification of other CT antigens
moved forward rapidly with the application of serological analysis
of recombinant expression libraries (SEREX) technology[40]. To
date at least forty four different CT antigens have been
recognized[41]. The reason why genes, which encode proteins
that are essential for spermatogenesis in the male or have a
structural role in sperm, are expressed in cancers is not clear. The
situation is complicated by the fact that the role of many of the CT
genes in spermatogenesis is poorly understood[36]. However, this
has not prevented the utilization of the CT antigens as biomarkers
for developing novel cancer diagnostics[42] and/or targets for
treatments such as immunotherapy[43]. One limiting factor in the
practical application of CT antigens has been the low frequency
with which the cancer/testis genes are expressed in any given
tumor type. This restriction is not present in the case of
spermatogenesis specific retrogene expression in ovarian cancers
as these genes are expressed in a relatively high percentage of
tumors.
An interesting feature of the previously recognized cancer/testis
genes and antigens is their disproportionate association with the X
chromosome[36]. The X chromosome and the genes it encodes
appear to play a pivotal role in tumor genesis and develop-
ment[44]. However, the relationship between tumor biology and
spermatogenesis is less clear. In man it appears that the testis
specific retrogenes are also be expressed in the ovary. However,
the specific cell types within which expression occurs remains to be
determined. Expression of these retrogenes may have a distinct
metabolic advantage for ovarian tumor development as it may
supplement gene products from the X chromosome, particularly in
cases where the progenitor gene activity is down regulated by
methylation[45] or lost due to deletion[34]. A link between
metabolic events occurring during spermatogenesis and cancer
development may be inferred from recent advances in the
understanding of cancer biology. Of special note is the recently
identified role of BRCA-1 in the development of breast and
ovarian cancers[46]. The BRCA-1 protein has been shown to be
associated with the inactive X chromosome in female somatic cells
and, during spermatogenesis, is localized to the inactive X
chromosome in pachytene spermatocytes during meiosis[47,48].
This suggests a shared regulatory pathway. Further work is needed
to determine the functional role of the spermatogenesis specific
retrogene products in both spermatogenesis and cancer. Expres-
Figure 4. Tissue-specific expression patterns of PGK1, PGK2,
RPL10, RPL10L, RPL39, RPL39L, UBL4A and UBL4B. Expression of the
X linked progenitor genes PGK1, RPL10, RPL39 and UBL4A is ubiquitous
as would be expected for genes encoding essential cellular functions. In
contrast expression of the spermatogenesis specific retrogenes, PGK2,
RPL10L, RPL39L and UBL4B, is predominantly limited to the testis. Tissue
key: AG, Adrenal Gland; BM, Bone Marrow; B, Brain; H, Heart; K, Kidney;
L, Liver; Lu, Lung; O, Ovary; Pl, Placenta; Pr, Prostate; SG, Salivary Gland;
SM, Skeletal Muscle; SC, Spinal Cord; T, Testis; Ty, Thyamus; Tr, Thyroid;
Tch, Trachea; U, Uterus. M is the molecular size marker and C, is the
primer only control reaction. The expression pattern for UTP14A and
UTP14C has been previously published[5].
doi:10.1371/journal.pone.0005064.g004
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TATA-independent promoters. Polyadenylation sites are up-
stream of those utilized in somatic cells and there is a
predominance of alternative pre-mRNA splicing[49]. The expres-
sion of testis specific genes and retrogenes suggests that cancer cells
are able to utilize the transcriptional and RNA processing
pathways normally active only during spermatogenesis in the
male testis. Any structural identity shared by the mRNAs
generated from the CT and other genes expressed in both cancers
and testis needs to be determined. If spermatogenesis and tumor
genesis share features of gene expression, regulation and RNA
processing one could speculate that in long lived mammals cancer
is a biological penalty of having separate sexes and the need for
spermatogenesis in particular.
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